Amgen Inc. $AMGN Shares Bought by Cornerstone Wealth Group LLC

Cornerstone Wealth Group LLC raised its position in Amgen Inc. (NASDAQ:AMGN) by 7.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 34,755 shares of the medical research company’s stock after acquiring an additional 2,365 shares during the quarter. Cornerstone Wealth Group LLC’s holdings in Amgen were worth $11,376,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. CWM LLC grew its position in Amgen by 4.2% in the 4th quarter. CWM LLC now owns 163,784 shares of the medical research company’s stock valued at $53,608,000 after acquiring an additional 6,643 shares in the last quarter. Slagle Financial LLC grew its position in shares of Amgen by 1.2% during the fourth quarter. Slagle Financial LLC now owns 8,483 shares of the medical research company’s stock worth $2,777,000 after buying an additional 98 shares in the last quarter. Diversified Management Inc. acquired a new position in shares of Amgen during the fourth quarter worth about $290,000. Childress Capital Advisors LLC grew its position in shares of Amgen by 48.1% during the fourth quarter. Childress Capital Advisors LLC now owns 3,718 shares of the medical research company’s stock worth $1,217,000 after buying an additional 1,207 shares in the last quarter. Finally, KBC Group NV grew its position in shares of Amgen by 17.9% during the fourth quarter. KBC Group NV now owns 572,145 shares of the medical research company’s stock worth $187,268,000 after buying an additional 86,723 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Performance

Shares of AMGN opened at $348.22 on Thursday. The stock has a 50 day moving average price of $363.86 and a 200 day moving average price of $336.66. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The company has a market capitalization of $187.93 billion, a price-to-earnings ratio of 24.47, a price-to-earnings-growth ratio of 3.30 and a beta of 0.47. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same period in the prior year, the company posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Research analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is 70.84%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on AMGN. Argus boosted their price objective on Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. TD Cowen reissued a “buy” rating on shares of Amgen in a research report on Wednesday, February 4th. The Goldman Sachs Group boosted their price objective on Amgen from $403.00 to $415.00 and gave the stock a “buy” rating in a research report on Wednesday, February 4th. Jefferies Financial Group began coverage on Amgen in a research report on Tuesday, March 10th. They set a “hold” rating and a $350.00 price objective for the company. Finally, Freedom Capital downgraded Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Amgen presently has a consensus rating of “Hold” and a consensus price target of $356.24.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.